Government and Taxes (Free subscription) | 11/21/2009
There was this news report last Thursday from Nature magazine. http://www.nature.com/naturejobs/2009/091119/full/nj7271-375e.html Published in Nature 462, 375 (18 November 2009) | 10.1038/nj7271-375e Huge cuts by drug firms R&D closure is the latest in a series of hits to drug companies. Pfizer is closing 35% of its global research and development space, according to a 9 November announcement....
Drug Injury Watch (Free subscription) | 11/20/2009
This Archive Contains Some "Secret" Documents Only Made Public In The Course Of Lawsuits Filed Against Pharmaceutical Companies (Posted by Tom Lamb at DrugInjuryWatch.com) Created and maintained by the University of California at San Francisco (UCSF), the Drug Industry Document Archive (DIDA) contains over 1500 documents, many of which were previously secret and only made public as a result...
Contract Pharma Breaking News (Free subscription) | 11/20/2009
Samir Ghodbane, Ph.D. , has been appointed as the new general manager of CMC services and CTM manufacturing at Frontage . Dr. Ghodbane has extensive experience and expertise in product development and technical operations spanning the complete product development cycle, as well as a comprehensive understanding of branded and generic pharmaceutical environments. He has led drug development and technical...
PharmaGossip (Free subscription) | 11/13/2009
« The Senate Plan's Resolution Authority | Main | Does Excess Debt Lead to Bubbles? » Nov 11 2009, 11:15 am by Derek Lowe Swinging The Ax At The Drug Companies Two big mergers are now shaking out in the drug business: Pfizer/Wyeth and Merck/Schering-Plough. Employees at the latter have told me that they're still waiting for the cuts that they know have to come, but the Pfizer and Wyeth...
Fiercebiotech (Free subscription) | 11/10/2009
New details on the impact of Pfizer's big R&D shakeup are coming in from around the world this morning. There's still no word on exactly how many of the 14,500 people working in research for Wyeth and Pfizer will be laid off. But the company said those cuts would make up a "considerable" segment of the 15 percent job cuts being planned across the board. Overall, Pfizer is shuttering...
The Washington Times (Free subscription) | 11/10/2009
TRENTON, N.J. | Less than a month after buying Wyeth, drug giant Pfizer Inc. has mapped out a new structure for its research and development operations. The plan, announced Monday, will close six of the two companies' 20 research facilities, reorganize and consolidate others, and cut the jobs of up to 2,000 scientists and laboratory technicians. Pfizer, which is based in New York, solidified its position...
Click here to see all comments
<a href= http://www.ugggoodsaler.com/ugg-classic-cardy-c-27.html >ugg classic cardy sale</a> <a href= http://www.ugggoodsaler.com/ugg-classic-cardy-c-27.html...
<a href= http://www.highqualityjeans.com/ >jeans on sale</a> <a href= http://www.highqualityjeans.com/mens-affliction-jeans-c-14.html >the special Men's...
San Fransisco Chronicle (Free subscription) | 11/10/2009
Pfizer Inc., which just acquired fellow drugmaker Wyeth, is closing six of the two companies' research sites and keeping open 14 others. Two Cambridge, Mass., sites will operate as one. Following is a list of the sites: Former Wyeth sites staying open/Types... Wyeth - Pfizer - Cambridge - Cambridge Massachusetts - England
Seattle Times (Free subscription) | 11/09/2009
Pfizer Inc., which just acquired fellow drugmaker Wyeth, is closing six of the two companies' research sites and keeping open 14 others. Two Cambridge, Mass., sites will operate as one. Following is a list of the sites:
France 24 (Free subscription) | 11/09/2009
Pfizer announced Monday cuts in its research activities and staff after acquiring pharmaceutical rival Wyeth. Research and development activities will now be conducted at five main sites and nine specialized units around the world, compared with 20 R&D sites on completion of the Wyeth deal in mid-October, a company statement said. "As part of the consolidation of research sites, Pfizer will...
PharmaGossip (Free subscription) | 11/05/2009
The U.S. Court of Appeals for the 8th Circuit has upheld Arkansas district court decisions in a products liability case against pharmaceutical companies that are the makers of hormone therapy drugs that, combined, have been linked to breast cancer. In Donna Scroggin, v. Wyeth, and its divisions; Pharmacia & Upjohn Company L.L.C., (Case Nos: 08-2555, 08-2711 and 08-2713) on appeal from the United...
Capital Observer (Free subscription) | 10/23/2009
Good Morning. The merger of Merck and Schering Plough has been approved by the EU and other approvals should be forthcoming in the weeks ahead. I have a position in Schering Plough and Merck but not nearly the size I had on the Pfizer/Wyeth combination. The reason being is that the spread on Pfizer/Wyeth was wider even though they had less overlap in their business. This was likely due to the larger...
Slice (Free subscription) | 10/22/2009
The traditional model for pharmaceutical public relations is to focus on the product brand, not the corporate brand. Healthcare consumers tend to identify more closely with product brand names rather than the company that controls that brand. Case in point: how many average consumers do you think realize that Wyeth makes Advil, that Johnson and Johnson [...]
PR News Wire (Free subscription) | 10/22/2009
WALTHAM, Mass., Oct. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs...
kansascity.com (Free subscription) | 10/21/2009
Pfizer’s acquisition last week of Wyeth will result in the closing of an Overland Park facility, affecting 200 jobs. The operation served as the headquarters of Fort Dodge Animal Health, a former Wyeth subsidiary. Most of Fort Dodge Animal Health’s business and administrative functions in Overland Park will move to Pfizer Animal Health’s Madison, N.J., headquarters, the...
Videos